204 related articles for article (PubMed ID: 28522196)
1. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Bonnet F; Scheen AJ
Diabetes Metab; 2017 Sep; 43(4):299-313. PubMed ID: 28522196
[TBL] [Abstract][Full Text] [Related]
2. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic drugs and stroke risk. Current evidence.
Castilla-Guerra L; Fernandez-Moreno MDC; Leon-Jimenez D; Carmona-Nimo E
Eur J Intern Med; 2018 Feb; 48():1-5. PubMed ID: 28939005
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
5. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
6. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
7. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
Busch RS; Kane MP
Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
[TBL] [Abstract][Full Text] [Related]
8. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
Scheen AJ; Delanaye P
Diabetes Metab; 2017 Apr; 43(2):99-109. PubMed ID: 28153377
[TBL] [Abstract][Full Text] [Related]
9. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
10. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
Arnold SV; Echouffo-Tcheugui JB; Lam CSP; Inzucchi SE; Tang F; McGuire DK; Goyal A; Maddox TM; Sperling LS; Fonarow GC; Masoudi FA; Kosiborod M
Am Heart J; 2018 Sep; 203():25-29. PubMed ID: 30015065
[TBL] [Abstract][Full Text] [Related]
11. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
Fitchett DH; Udell JA; Inzucchi SE
Eur J Heart Fail; 2017 Jan; 19(1):43-53. PubMed ID: 27653447
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
[TBL] [Abstract][Full Text] [Related]
14. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
16. Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.
Benn M; Emanuelsson F; Tybjærg-Hansen A; Nordestgaard BG
Diabetologia; 2021 Jul; 64(7):1492-1503. PubMed ID: 33765180
[TBL] [Abstract][Full Text] [Related]
17. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
18. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors.
Scheen AJ
Diabetes Metab; 2022 Nov; 48(6):101405. PubMed ID: 36334794
[TBL] [Abstract][Full Text] [Related]
19. Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials.
Lim S; Oh TJ; Dawson J; Sattar N
Diabetes Obes Metab; 2020 Jan; 22(1):6-15. PubMed ID: 31379119
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
